ASX biotechs join global race for cell therapy breakthroughs
Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally
Chimeric aims to 'break new ground' in treatment of solid tumours with CAR-T and NK cell assets
Cell therapies represent a promising frontier in modern medicine, offering potential to treat, and in some cases cure diseases previously considered untreatable.
By using living cells, either from the patient (autologous) or a donor (allogeneic), cell therapies aim to repair, replace, or enhance biological functions within the body.
Originally pioneered for blood cancers through technologies like chimeric antigen receptor (CAR) T-cell therapies, the field is rapidly expanding into solid tumours, autoimmune conditions, and neurological diseases.
Australia has close ties to CAR T-cell therapy development. Melbourne-based Cell Therapies Pty Ltd, the country's largest Therapeutic Goods Administration (TGA) licensed cell and gene therapy manufacturer, was the commercial production partner for Novartis's Kymriah – the first CAR T-cell therapy approved by the US Food and Drug Administration (FDA) in 2017.
While the science remains complex, advances in manufacturing, engineering, and clinical design are making next-generation cell therapies more accessible and scalable, positioning them as a key pillar of future healthcare.
Several ASX biotechs are positioning themselves at the forefront of cell therapies to capture a share of the global market, which accounted for ~US$6.04 billion in 2024 and is anticipated to close in on US$48bn by 2034, growing at a CAGR of almost 23%.
In particular focus here is the treatment of solid tumours, which account for 90% of all cancers but have so far proven difficult to treat with cell therapies.
Arovella in rare biotech club targeting CAR-iNKT therapies
Arovella Therapeutics (ASX:ALA) is the only ASX-listed biotech delving into CAR Invariant Natural Killer T-cells (iNKT) therapies, and one of only a few globally.
CEO Dr Michael Baker told Stockhead iNKT cells were distinct from the more familiar natural killer, or NK cells, which along with T-cells had limitations.
T-cells can't be used off-the-shelf unless they are genetically engineered. While NK cells can quickly eliminate abnormal cells such as tumour cells, iNKT cells go further. Not only do they kill like T and NK cells, but they also trigger a longer-lasting response by activating other key parts of the immune system.
Because iNKT cells recognise foreign threats differently – unlike classic CAR-T cells – it has been shown in clinical trials that iNKT cells do not cause complications like graft-versus-host disease (GvHD) when administered from a healthy donor to a patient.
The FDA has approved seven CAR-T therapies to date, all for blood cancers, but no iNKT treatments.
While over 120 global trials are investigating CAR-NK therapies for blood and solid tumours, CAR iNKT research remains limited.
Baker said most cell therapies use the patient's own cells (autologous), but this was costly, slow, and relies on compromised cells.
Arovella is taking an allogeneic approach, using healthy donor cells to create off-the-shelf, frozen doses shipped to clinics as needed in a 'ready-to-use' model.
Its lead therapeutic ALA-101 combines iNKT cells with a CAR that targets CD19, a protein commonly found on B-cell blood cancers like lymphoma and leukaemia.
One of Arovella's next key milestones is to apply to the FDA for its first-in-human trial, enrolling non-Hodgkin's lymphoma and leukaemia patients.
The company's other key goal is also tackling solid tumours.
"The first approved blood cancer targeting CAR-T products have demonstrated just how important cell therapies will be for cancer treatment," Baker said.
"We look forward to using our CAR-iNKT cell platform to expand upon that work and aim to create products capable of increasing access and reducing costs.
"There is a lot of great science that will continue to advance the off-the-shelf cell therapy sector.
"That is why we continue to scour the globe for new IP to build into our CAR-iNKT platform, to either strengthen our CAR-iNKT cells or to broaden the cancer types that we can target.'
Imugene also aims to crack solid tumours
Imugene (ASX:IMU) is developing cell-based immunotherapies, including allogeneic CAR T-cell therapies, oncolytic viruses and B-cell vaccines, to address both blood cancers and solid tumours.
The company's lead cell therapy candidate azercabtagene zapreleucel (azer-cel) is an off-the-shelf CAR T-cell therapy targeting CD19, a protein commonly expressed on malignant B-cells. There are no allogeneic (off the shelf) CAR T therapies approved to date.
Azer-cel is currently undergoing clinical trials for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), a hard-to-treat form of non-Hodgkin's lymphoma.
In early-phase studies, azer-cel has demonstrated promising results, including high complete response rates and durable remissions in patients who have previously relapsed after autologous CAR T-cell therapies.
"We are very pleased with the continued positive data coming from the azer-cel trial, which further reinforces its potential as a treatment for lymphoma patients who have failed on several previous therapies including auto CAR T," CEO and managing director Leslie Chong told Stockhead.
Imugene's next-generation cell therapy platform OnCARlytics is designed to help overcome one of the biggest challenges in cancer treatment, making solid tumours visible to the immune system.
The approach combines Imugene's proprietary CF33 oncolytic virus, which selectively infects and destroys cancer cells, with CD19-targeting CAR T-cells.
The CF33 infects tumour cells and forces them to express CD19, a marker typically found on blood cancer cells but absent on solid tumours.
By introducing CD19 into the tumour environment, the therapy effectively tags the cancer, allowing CD19-specific CAR T-cells to recognise and attack the tumour.
Imugene's pipeline also includes multiple immunotherapy B-cell vaccine candidates, which involve inducing the body to produce polyclonal antibodies against specific tumour-associated antigens.
The company's PD1-Vaxx is designed to generate antibodies that block the PD-1 receptor, potentially mimicking the effects of checkpoint inhibitors such as pembrolizumab (Keytruda).
The company recently announced the first patient had been dosed in Australia as part of an investigator-sponsored Phase II Neo-POLEM clinical trial, which is evaluating PD1-Vaxx's potential to improve treatment outcomes for patients with mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-high) colorectal cancer.
This aggressive cancer subtype accounts for ~15% of all colorectal cancer cases.
Chimeric advances cell therapy assets in solid tumours
Chimeric Therapeutics (ASX:CHM) has three CAR T and NK cell assets in clinical trials. It has an ongoing phase 1/2 clinical trial for its novel CHM CDH17 CAR T-cell therapy targeting advanced colorectal cancer and Neuroendocrine tumours of the midgut.
Their second program CHM CLTX CAR T is in a phase 1B clinical trial in recurrent/progressive glioblastoma, a form of brain cancer.
CHM CORE-NK is a potentially best-in-class, clinically validated NK cell platform. Data from the complete phase 1A clinical trial, demonstrated safety and efficacy in blood cancers and solid tumours.
Two additional Phase 1B clinical trials investigating CHM CORE-NK in combination regimens have been initiated in Acute Myeloid Leukemia (AML).
"We're excited to be actively advancing in the clinic and pushing through dose levels as we break new ground in the solid tumour CAR T-cell therapy space," CEO Dr Rebecca McQualter told Stockhead.
Prescient advancing cell therapy platforms
While predominately focused on PTX-100, its first-in-class compound with the ability to block an important cancer growth enzyme geranylgeranyl transferase-1 (GGT-1), Prescient Therapeutics (ASX:PTX) is also advancing its proprietary OmniCAR and CellPryme platforms.
OmniCar has potential to allow CAR T therapy cells to be more targeted, safer, more effective, cost-effective and of longer duration.
CellPryme is a complementary application to OmniCar split into two components. CellPryme-M produces superior cells that are more potent and last longer, aiming to double tumour control.
Meanwhile, CellPryme-A acts as an adjuvant therapy, increasing the expansion of CAR T-cells and enhancing their ability to penetrate the tumour.
AdAlta adopts East to West cellular immunotherapy strategy
AdAlta (ASX:1AD) and venture capital firm SYNthesis BioVentures Fund (SYNBV) launched AdCella in 2024 to adopt an East to West strategy and bring cutting-edge cellular immunotherapies from Asia, particularly China, into Western markets.
SYNBV was co-founded by Professor Andrew Wilks, who alongside Amplia (ASX:ATX) CEO Dr Chris Burns received the 2024 Prime Minister's Prize for Innovation for co-inventing momelotinib, an FDA-approved treatment for myelofibrosis.
The strategy leverages AdAlta managing director and CEO Dr Tim Oldham's deep expertise in cellular immunotherapies and extensive operational experience in Asia to identify and advance promising Asian cellular therapies that can be transitioned into regulated western markets.
Oldham was previously CEO of Cell Therapies and said he'd been fortunate to witness firsthand the rapid evolution of China's biotech sector and remarkable progress in cellular immunotherapies for cancer treatment over the past 15 years.
The East to West cellular immunotherapy strategy for cancer is now a core growth priority for AdAlta and a key driver of future pipeline growth and value creation.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
SBS Australia
3 hours ago
- SBS Australia
Australia's hermit crabs are in demand globally but some want the trade banned
A push to export hermit crabs from Western Australia has sparked criticism, with one political party calling to ban the trade over concerns about animal welfare and environmental impact. Merv Cooper runs Crazy Crabs in Western Australia — a business operating since 1979, specialising in the sale of Australian land hermit crabs. He sells these to Australian pet stories, and also exports them internationally to locations including Hong Kong and the United States. But his export permit expired late last year and the federal Department of Climate Change, Energy, the Environment and Water (DCCEEW) is now assessing a three-year extension — a move the Animal Justice Party says would be "reckless and short-sighted". SBS News attempted to contact Cooper for comment but he was unavailable. Experts say it's difficult to know whether harvesting the crustaceans is sustainable, due to regulatory gaps in Australia's hermit crab trade. A little-known industry The species — Coenobita variabilis — is endemic to Australia, found only along the north-western coast of Western Australia and in parts of the Northern Territory. In its proposal to the DCCEEW, Crazy Crabs said the business collects on average 30,000 crabs each. In summer, he and a small crew head out for four to six days at a time, collecting crabs at night on foot using torches and buckets. "Really small" crabs are left on the beach. It says collections happen "only a couple of times a year" and these don't "appear to have any detriment on populations". But reliable data on hermit crab harvesting is scarce. During a typical year, Merv Cooper collects 30,000 crabs from Western Australian beaches — which he sends off to pet shops across Australia. Source: Getty / Jamie La Australian states and territories are responsible for domestic trade, including licensing requirements. This makes it difficult to determine the exact number of active hermit crab export operators in Australia, the quantity of crabs they collect, and the potential impact of this activity. According to an ABC report in 2022, WA Fisheries data indicated around 80,000 land hermit crabs were collected by two active operators that year. At the time, they estimated the commercial value of a hermit crab licence to be between $1 million and $5 million. A DCCEEW spokesperson said the federal government "strictly regulates commercial trade in wildlife and wildlife products from Australian native species, such as hermit crabs. Animal Justice Party MPs say the application highlights a lack of scientific rigour in how such trades are assessed — and could open the door to further exploitation. "This proposal is a stark example of the federal government's failure to uphold rigorous scientific and environmental standards," said Victorian upper house MP Georgie Purcell, "Allowing the commercial export of a native species without comprehensive ecological assessments is reckless and short-sighted." WA upper house MP Amanda Dorn said she is concerned that if the trade is allowed to continue with little regulation, "fragile ecosystems" could be "irreversibly" damaged. In its proposal, Crazy Crabs said WA's Department of Primary Industries and Regional Development does not consider Coenobita variabilis to be in need of formal management plans for protection. It said the number of crabs and the locations where they were collected are reported monthly, as required by state licensing laws. "I have been collecting Hermit crabs for over 50 years and have never seen any need for restrictions," the proposal reads." I don't go to all places every year, hence there is always plenty of hermit crabs." Tim Nichols, a manager at WA Fisheries, told the ABC in 2022 the species was abundant and their population was unlikely to be affected by the current level of fishing. 'Relying on self-reporting': Expert raises concerns Kim Feddema, a wildlife trade expert and lecturer at Edith Cowan University, said the trade relies heavily on licence-holders to assess their own environmental impact, with no baseline population data or independent monitoring. "We need to understand how many hermit crabs are actually in those locations and what role they play in the broader ecology," she told SBS News. "Without baseline data, there's no way to judge the sustainability of this kind of trade." While the international export of native species is subject to federal regulation, hermit crabs are not formally listed as protected. Invertebrates often fall through regulatory gaps, Feddema said, because they're harder to monitor and traditionally not perceived as sentient. Kim Feddema, a wildlife trade expert, said more regulation is necessary in the industry to ensure the welfare of hermit crabs and to understand the environmental implications of their removal. Credit: Stephen Heath / Edith Cowan University Globally, land hermit crabs are harvested for both the pet and shell trade. While shells are often sold as decorations, Feddema notes they once housed live animals. "People often perceive [shells] to be empty, but there is a live animal within them before that stage," she said. Across Asia, including Thailand and Japan, this dual trade has already been linked to population declines. While Australia requires permits to collect hermit crabs at a commercial level, enforcement is limited and operators are not independently monitored. "We're relying on self-reporting here," Feddema said. "There's no verification of what's being collected or the long-term impact on local populations." Are hermit crabs suitable pets? Hermit crabs play a vital role in their native ecosystems, Feddema said, acting as "ecosystem engineers". They recycle shells that would otherwise be buried by sand, creating homes for algae, sponges, and other small organisms. They also help with nutrient recycling by scavenging on waste and decaying animals. But despite this ecological importance, hermit crabs are often marketed as low-maintenance pets — sold in pet stores and online — a characterisation Feddema said is misleading. She said in the wild, they can live for over thirty years. In captivity, however, their lifespans are often significantly shortened — sometimes surviving only a few months or years. She compared the industry to the "cut flower trade", where high mortality rates are treated as inevitable. "People sometimes treat pets the same way they treat cut flowers — that they'll have them for a short period of time and then accept a certain level of mortality," she said. In its proposal, Crazy Crabs said its experience in taking, holding and transporting hermit crabs "has reduced the mortality rate during transit to practical zero for the last ten years". Demand for rare and large individuals is also growing, raising concerns about overharvesting ecologically important crabs that produce a high number of offspring. Studies have shown hermit crabs exhibit signs of sentience, including problem solving, memory and a response to pain — which Feddema said challenges assumptions that invertebrates do not require additional welfare standards. "There is a question about how appropriate they are to be held in captivity," she said. "If the owner doesn't have the particular needs and they're not able to recognise the complexity of owning a hermit crab." She said reforms are urgently needed to assess population health and establish long-term data. "It is very possible that this is a trade that is sustainable, but we just can't make that decision without the data behind it."
News.com.au
4 hours ago
- News.com.au
Arts Centre builder's family home sold in Burwood
A Burwood home built by the man who helped supervise works on Melbourne landmarks including the Arts Centre and RMIT has sold to a local family who plan to preserve its character. The four-bedroom house at 30 Leopold St changed hands for $1.775m, with buyers drawn to its spacious floorplan, 836sq m block, and original features, including a spa, sauna and swimming pool, which were ahead of their time when built in the early 1970s. Buxton Mount Waverley's Peter Serafino said the home attracted strong local interest and was never seriously considered for demolition. Melb property market tipped to hit new record 'The buyers are a family from the area who fell in love with it,' Mr Serafino said. 'They're planning to renovate rather than rebuild, which is the perfect outcome. It's rare to find a home like this in such great condition.' Seller Leonie Vella, who grew up in the home with her sister Kim, said their late father John Vella was a construction supervisor who worked on the Arts Centre and the RMIT building. 'Dad was a builder through and through, but he also had heart,' Ms Vella said. 'He built this house for us. Every brick was perfectly placed, and Mum made sure it was always immaculate. 'It still has her curtains hanging from the '70s.' Ms Vella's late mother June played a major role in the home's interior and garden design. 'Mum had so much flair. She planted flowers along the brick walls and kept the formal lounge for Christmas only,' she said. 'It was pristine, but always warm. 'She took pride in every detail, right up to the end.' The property features two large living areas, a bar, terraced gardens, and an undercover alfresco area that once hosted pool parties, family milestones and holiday celebrations. 'We had every kind of event here, engagements, Christmases, sleepovers,' Ms Vella said. 'It was the kind of house that was always full of life and joy.' Ms Vella said knowing the home would be loved again gave the family comfort. 'That's what Dad would've wanted,' she said. 'There is this warmth that never left, like the love stayed in the walls.'
News.com.au
4 hours ago
- News.com.au
The ‘new normal' leaving Aussie first homebuyers behind
In a modest suburb an hour southeast of Western Australia's capital city, Perth, a tiny three-bedroom home on a 187 square metre block is expected to sell for nearly $700,000. Just three years ago, the home in Piara Waters would have sold for around $450,000. This equal parts dramatic and depressing increase exemplifies what real estate agent Aman Singh describes as the 'new normal' in Perth's housing market. 'You have seen the demand. This property is the only one available within this price range. So people are jumping on it,' Mr Singh told Brooko Moves. 'What's applying in Piara Waters at the moment is demand and supply.' It's a staggering statement when you consider the national average block size for a three-bedroom, two-bathroom home is more than double at 450 square metres. Mr Singh's stark advice is further proof of a market that isn't just out of control, but out of reach for most first homebuyers. 'Put your best offer forward, there may not be a second opportunity,' he insisted. He added that many properties were receiving multiple offers and often exceeded the asking price by $30,000 to $40,000. Of course this surge in property prices is not isolated to Piara Waters, a fairly new concrete city estate development where houses are mere centimetres apart and green spaces are scant. Across Perth, the median house price rose to $855,395 as of June 2025, which was a 7.8 per cent increase from June 2024. Even more terrifyingly, analysts predicted growth of up to 10 per cent more by the end of the year. It's a challenging time to be a first homebuyer, to say the least. Mr Singh said about 70 to 75 per cent of interested buyers were first-timers, and many were beginning to display their frustration. 'First homebuyers are more emotional buyers and quite often disgruntled, missing out on properties one after another,' he said. 'By the time they reach the sixth property and make an offer, they expect it to be accepted.' Still, Mr Singh urged first homebuyers to get into the market ASAP. 'That's the only way to get out of the rent trap because you are ultimately paying for somebody else's mortgage.' He remained insistent that right now was the best time to buy, encouraging buyers to ignore the possibility of a slump in about two years. 'For everyone, especially first-time buyers, get into the market as soon as you can,' he said. 'I don't believe the market's going to come down anytime soon, at least not for the next two years.' The situation in Perth reflects a broader national trend. In the March quarter of 2025, the average price of a residential dwelling in Australia surpassed $1 million for the first time in another punch to the gut for first homebuyers across the country. Prospective buyers have no choice but to attempt to craftily navigate a property landscape marked by rapid price increases, intense competition and limited opportunities. The Great Australian Dream for a growing number of young Aussies is starting to look more like a very expensive joke.
